AQST
Neutral signalScored 2026-10-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Aquestive Therapeutics, Inc.
- Nom
- Aquestive Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $502.0M
- Employés
- 147
- PDG
- Daniel Barber
- Site web
- https://www.aquestive.com
- Marché
- ALKSAMPHAYTUCOLLCPIXDERM
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 000 titres (~226 087,50 $ US)
- Insiders
- Barber Daniel
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$378,930
Avg sell (VWAP, 90d window) $4.52 vs last close $4.13 (-8.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$378,930 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Thin $9,012,021/day · 20d vol
- Last synced
-
2026-10-22 21:10:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Barber Daniel | Sell · S · 10b5-1 | 25,000 | $4.22 | $105,600 | Form 4 |
| 2026-09-15 | Barber Daniel | Sell · S · 10b5-1 | 25,000 | $4.82 | $120,487 | Form 4 |
| 2026-09-09 | Korczynski Sherry | Sell · S · 10b5-1 | 8,750 | $5.22 | $45,675 | Form 4 |
| 2026-08-17 | Barber Daniel | Sell · S · 10b5-1 | 25,000 | $4.29 | $107,168 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
AQST carries a meaningful regulatory catalyst with the FDA-accepted Anaphylm NDA resubmission (PDUFA March 16, 2027), but the underlying financials are severely distressed — net margins at -188%, surging…
The first sentence of the analysis written for AQST on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $379K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $379K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.14 · operating margin -156% — readings disagree
Suggested stop 3.86, nearest stored support minus 0.5 ATR(6.5% under the last close). Reward/risk to the next stored resistance is 0.19. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317
- 2026-10-16 Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade Aquestive Therapeutics received FDA acceptance for the Anaphylm NDA resubmission, targeting a March 16, 2027 PDUFA date. Resubmission addresses prior FDA concerns with improved human factors data, showing a significant reduction in packaging and administration errors. I upgrade AQST to Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030, despite competitive and reimbursement risks.
- 2026-10-15 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, in keeping with the FDA''s classification of the resubmission as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis.
- 2026-10-07 Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising from alleged false and misleading statements about the company''s drug candidate Anaphylm. Current shareholders are encouraged to contact the firm here: https://www.classactionlawyers.com/aquestive.
- 2026-09-29 Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company''s Board of Directors, effective October 14, 2026.
- 2026-09-24 Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC Squarepoint Ops LLC reduced its position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) by 71.8% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,422 shares of the company''s stock after selling 179,060 shares during the period. Squarepoint Ops LLC owned about
- 2026-09-17 Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026 FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.
- 2026-09-02 8,069,373 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by BlackRock Inc. BlackRock Inc. bought a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,069,373 shares of the company''s stock, valued at approximately $33,569,000. BlackRock Inc. owned 6.43% of Aquestive Therapeutics as of its most recent
- 2026-09-01 Aquestive Therapeutics to Participate in Upcoming September Investor Conferences WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:
- 2026-08-26 AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQST AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 475,400 shares of the company''s stock, valued at approximately $1,978,000. AWM Investment Company Inc. owned
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.5% | 69.0% | 58.8% | 59.3% | 70.5% | |
| Ebit Margin | -149.7% | -47.5% | -0.3% | -88.0% | -94.6% | |
| Ebitda Margin | -148.5% | -46.2% | 2.3% | -83.0% | -88.8% | |
| Operating Profit Margin | -156.4% | -53.5% | -29.9% | -88.2% | -68.2% | |
| Pretax Profit Margin | -188.1% | -76.7% | -15.1% | -114.1% | -138.8% | |
| Continuous Operations Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Net Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Bottom Line Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | |
| Current Ratio | 3.135 | 4.676 | 2.238 | 1.009 | 2.152 | |
| Quick Ratio | 3.006 | 4.356 | 1.868 | 0.863 | 1.968 | |
| Solvency Ratio | -0.429 | -0.269 | -0.040 | -0.296 | -0.469 | |
| Cash Ratio | 2.545 | 3.793 | 1.304 | 0.690 | 1.276 | |
| Price To Earnings Ratio | -8.500 | -6.980 | -15.538 | -0.805 | -2.103 | |
| Price To Earnings Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Forward Price To Earnings Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Price To Earnings Diluted Ratio | -8.500 | -6.980 | -15.538 | -0.805 | -2.103 | |
| Price To Earnings Diluted Growth Ratio | -0.173 | -0.024 | 0.176 | 0.020 | -0.184 | |
| Price To Book Ratio | -23.406 | -5.132 | -1.162 | -0.371 | -1.803 | |
| Price To Sales Ratio | 17.688 | 5.364 | 2.446 | 0.922 | 2.914 | |
| Price To Free Cash Flow Ratio | -14.868 | -8.596 | -16.778 | -3.570 | -4.370 | |
| Price To Operating Cash Flow Ratio | -15.027 | -8.634 | -19.394 | -4.491 | -4.491 | |
| Debt To Assets Ratio | 0.819 | 0.375 | 0.580 | 1.007 | 0.910 | |
| Debt To Equity Ratio | -3.905 | -0.632 | -0.313 | -0.485 | -0.687 | |
| Debt To Capital Ratio | 1.344 | -1.716 | -0.455 | -0.941 | -2.194 | |
| Long Term Debt To Capital Ratio | 1.411 | -1.175 | -0.348 | -0.393 | -1.686 | |
| Financial Leverage Ratio | -4.766 | -1.686 | -0.539 | -0.481 | -0.755 | |
| Working Capital Turnover Ratio | 0.521 | 1.251 | 4.395 | 3.717 | 2.083 | |
| Operating Cash Flow Ratio | -1.101 | -1.896 | -0.348 | -0.248 | -1.502 | |
| Operating Cash Flow Sales Ratio | -1.177 | -0.621 | -0.126 | -0.205 | -0.649 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.011 | 1.004 | 1.156 | 1.258 | 1.028 | |
| Debt Service Coverage Ratio | -2.302 | -1.579 | 0.125 | -1.271 | -1.842 | |
| Interest Coverage Ratio | -4.073 | -1.830 | -2.024 | -3.381 | -1.544 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.510 | -1,375.346 | -290.000 | -0.523 | -16.286 | |
| Operating Cash Flow Coverage Ratio | -0.399 | -0.941 | -0.191 | -0.170 | -0.585 | |
| Capital Expenditure Coverage Ratio | -93.295 | -224.899 | -6.412 | -3.878 | -36.122 | |
| Dividend Paid And Capex Coverage Ratio | -93.295 | -224.899 | -6.412 | -3.878 | -36.122 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.069 | -10.340 | 112.677 | -1.874 | -3.913 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.5% | ▼-7.5% | ▼-2.3% |
| Ebit Margin | -149.7% | ▼-102.2% | ▼-73.7% |
| Ebitda Margin | -148.5% | ▼-102.2% | ▼-75.6% |
| Operating Profit Margin | -156.4% | ▼-102.9% | ▼-77.1% |
| Pretax Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Continuous Operations Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Net Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Bottom Line Profit Margin | -188.1% | ▼-111.4% | ▼-81.5% |
| Current Ratio | 3.135 | ▼-1.541 | ▲0.493 |
| Quick Ratio | 3.006 | ▼-1.350 | ▲0.594 |
| Solvency Ratio | -0.429 | ▼-0.160 | ▼-0.128 |
| Cash Ratio | 2.545 | ▼-1.247 | ▲0.624 |
| Price To Earnings Ratio | -8.500 | ▼-1.520 | ▼-1.715 |
| Price To Earnings Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Forward Price To Earnings Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Price To Earnings Diluted Ratio | -8.500 | ▼-1.520 | ▼-1.715 |
| Price To Earnings Diluted Growth Ratio | -0.173 | ▼-0.149 | ▼-0.136 |
| Price To Book Ratio | -23.406 | ▼-18.274 | ▼-17.031 |
| Price To Sales Ratio | 17.688 | ▲12.324 | ▲11.821 |
| Price To Free Cash Flow Ratio | -14.868 | ▼-6.272 | ▼-5.231 |
| Price To Operating Cash Flow Ratio | -15.027 | ▼-6.393 | ▼-4.620 |
| Debt To Assets Ratio | 0.819 | ▲0.445 | ▲0.081 |
| Debt To Equity Ratio | -3.905 | ▼-3.273 | ▼-2.701 |
| Debt To Capital Ratio | 1.344 | ▲3.060 | ▲2.137 |
| Long Term Debt To Capital Ratio | 1.411 | ▲2.587 | ▲1.849 |
| Financial Leverage Ratio | -4.766 | ▼-3.080 | ▼-3.120 |
| Working Capital Turnover Ratio | 0.521 | ▼-0.730 | ▼-1.872 |
| Operating Cash Flow Ratio | -1.101 | ▲0.794 | ▼-0.082 |
| Operating Cash Flow Sales Ratio | -1.177 | ▼-0.556 | ▼-0.621 |
| Free Cash Flow Operating Cash Flow Ratio | 1.011 | ▲0.006 | ▼-0.081 |
| Debt Service Coverage Ratio | -2.302 | ▼-0.723 | ▼-0.928 |
| Interest Coverage Ratio | -4.073 | ▼-2.243 | ▼-1.503 |
| Short Term Operating Cash Flow Coverage Ratio | -4.510 | ▲1370.836 | ▲332.823 |
| Operating Cash Flow Coverage Ratio | -0.399 | ▲0.542 | ▲0.058 |
| Capital Expenditure Coverage Ratio | -93.295 | ▲131.604 | ▼-20.374 |
| Dividend Paid And Capex Coverage Ratio | -93.295 | ▲131.604 | ▼-20.374 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.069 | ▼-1.729 | ▼-28.965 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $787.9M | $308.7M | $123.7M | $44.0M | $148.1M | |
| Enterprise value | $798.2M | $275.2M | $133.2M | $74.2M | $176.5M | |
| EV / Sales | 17.92x | 4.78x | 2.63x | 1.56x | 3.47x | |
| EV / Op. cash flow | -15.22x | -7.70x | -20.88x | -7.58x | -5.35x | |
| EV / Free cash flow | -15.06x | -7.66x | -18.06x | -6.02x | -5.21x | |
| EV / EBITDA | -12.07x | -10.34x | 112.68x | -1.87x | -3.91x | |
| Net debt / EBITDA | -0.15x | 1.26x | 7.99x | -0.76x | -0.63x | |
| Current ratio | 3.13x | 4.68x | 2.24x | 1.01x | 2.15x | |
| Income quality | 0.63x | 0.81x | 0.81x | 0.18x | 0.47x | |
| Graham net-net | -$0 | -$1 | -$2 | -$3 | -$3 | |
| Tax burden | 100.0% | 100.0% | 103.2% | 100.0% | 100.0% | |
| Interest burden | 125.6% | 161.5% | 4677.9% | 129.6% | 146.7% | |
| Working capital | $101.7M | $69.4M | $22.7M | $360K | $25.3M | |
| Invested capital | $110.2M | $78.3M | $33.7M | $11.1M | $33.1M | |
| Return on assets | -52.2% | -43.5% | -13.7% | -95.3% | -113.8% | |
| Operating ROA | -53.2% | -38.7% | -26.4% | -70.7% | -55.5% | |
| Return on tangible assets | -52.2% | -43.5% | -14.0% | -97.8% | -113.9% | |
| Return on equity | 248.9% | 73.4% | 7.4% | 45.9% | 85.9% | |
| Return on invested capital | -56.0% | -37.0% | -38.2% | -115.3% | -80.7% | |
| Return on capital employed | -61.7% | -37.3% | -38.6% | -239.8% | -86.6% | |
| Earnings yield | -10.6% | -14.3% | -6.4% | -123.8% | -47.6% | |
| Free cash flow yield | -6.7% | -11.6% | -6.0% | -28.0% | -22.9% | |
| Capex / Op. cash flow | -1.1% | -0.4% | -15.6% | -25.8% | -2.8% | |
| Capex / Depreciation | 102.6% | 22.1% | 74.0% | 105.7% | 30.8% | |
| Capex / Sales | 1.3% | 0.3% | 2.0% | 5.3% | 1.8% | |
| SG&A / Sales | 179.3% | 87.2% | 62.8% | 110.9% | 105.2% | |
| R&D / Sales | 38.6% | 35.2% | 25.9% | 36.7% | 33.5% | |
| Stock comp / Sales | 17.1% | 12.3% | 5.3% | 9.2% | 13.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 2.2% | 2.5% | 0.1% | |
| Days sales outstanding | 146d | 47d | 61d | 36d | 87d | |
| Days payables outstanding | 635d | 210d | 156d | 187d | 202d | |
| Operating cycle | 277d | 170d | 180d | 145d | 185d | |
| Cash conversion cycle | -359d | -40d | 23d | -42d | -17d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years